ライフサイエンスコーパス: mifepristone

1 active in the presence of the steroid RU486 (mifepristone).

2 ends on the presence of the activator RU486 (mifepristone).

3 ility (<50% of available pharmacies dispense mifepristone).

4 nist dexamethasone and the antagonist RU486 (mifepristone).

5 as induced in hepatocytes after injection of mifepristone.

6 n vivo models,4h had potencies comparable to mifepristone.

7 lucocorticoid receptor (GR) antagonists like mifepristone.

8 not be administered strictly 48 hours after mifepristone.

9 isoprostol with or without pretreatment with mifepristone.

10 osed by the Food and Drug Administration for mifepristone.

11 were reversed by the GC receptor antagonist mifepristone.

12 pothalamic-pituitary-adrenal axis (HPA) with mifepristone.

13 es and is not inhibited by the GR antagonist mifepristone.

14 by the magnitude of the cortisol response to mifepristone.

15 Structure-based modification of mifepristone (1) led to the discovery of novel mifeprist

16 the progesterone receptor antagonist RU486 [mifepristone (11beta-[p-(dimethylamino)phenyl]-17beta-hy

17 omly assigned (1:1) to a single dose of oral mifepristone 200 mg or an oral placebo tablet, both foll

18 recommended alternative approaches, such as mifepristone, 200 mg orally, followed in 1 to 3 days by

19 Mifepristone, 200 mg, and misoprostol, 800 ug, prescribe

20 0 microg, can be used from 1 to 3 days after mifepristone, 200 mg, for early medical abortion, and ne

21 llowed by subcutaneous injection of vehicle, mifepristone 30 mg/kg, propranolol 10 mg/kg, or both.

22 or the combined regimen of misoprostol plus mifepristone (356 participants).

23 elative to placebo, individuals who received mifepristone (600 mg daily taken orally for 1 week) exhi

24 rticipants were randomized in a 1:1 ratio to mifepristone (600 mg) or matched placebo taken orally fo

25 Food and Drug Administration specifies mifepristone, 600 mg orally, followed 2 days later by mi

26 ic potential of reducing Klf15 activity with mifepristone, a glucocorticoid antagonist, combined with

27 ctive of this study was to determine whether mifepristone, a glucocorticoid receptor antagonist, play

28 the US Food and Drug Administration (FDA) of mifepristone, a medication used to terminate pregnancy,

29 nce pharmacist referral networks and improve mifepristone access, as well as service planning for int

30 llowed by truncation of Bid, confirming that Mifepristone activates the TRAIL pathway.

31 at both systemic and intra-CeA (but not BLA) mifepristone administration suppressed yohimbine-induced

32 ls without previous olaparib exposure, while mifepristone alone decreased tumor growth in PDX models

33 armacologic treatment with the GR antagonist mifepristone also attenuated disease as effectively as h

34 Chronic treatment with mifepristone also blocked escalated alcohol drinking and

35 endometritis following medical abortion with mifepristone (also known as RU-486) used with misoprosto

36 5-year trends following normally prescribed mifepristone, although social forces potentially impacti

37 The stimulation can be eliminated by mifepristone, an antagonist of GR, indicating the involv

38 Mifepristone, an antiprogestin used individually or toge

39 Here we generate a suite of new mifepristone analogues with enhanced antiviral propertie

40 s, defined as complete abortion after 200 mg mifepristone and 1,600 mug misoprostol (or lower) withou

41 ntention-to-treat analysis (41 randomized to mifepristone and 39 to placebo).

42 Participants in this group took 200 mg mifepristone and 800 mug misoprostol at home.

43 gible patients, 80 were randomly assigned to mifepristone and 84 to placebo.

44 Mifepristone and a prostaglandin have been used successf

45 men were randomly assigned to receive either mifepristone and misoprostol (357 women) or placebo and

46 report the results of a large U.S. study of mifepristone and misoprostol in women with pregnancies o

47 ever, it is unclear whether a combination of mifepristone and misoprostol is more effective than admi

48 abortion without the need for repeating the mifepristone and misoprostol regimen or a follow-up proc

49 ion abortion through an in-person screening, mifepristone and misoprostol were prescribed using a mai

50 ment of miscarriage, medical management with mifepristone and misoprostol, and surgical management wi

51 Medication abortion, with a combination of mifepristone and misoprostol, is highly effective and sa

52 Mifepristone and Tamoxifen induced significant expressio

53 The anti-progesterone drug mifepristone and the prostaglandin misoprostol can be us

54 We administered 600 mg of mifepristone and then 400 microg of misoprostol two days

55 a narrow class of antiprogestins, including mifepristone and ulipristal, and whose expression is med

56 efined as complete abortion after 200 mug of mifepristone and up to 1600 mug of misoprostol without a

57 Patients received 200 mg of oral mifepristone and were randomly assigned to self-administ

58 ctivation (potency within 10-fold of that of mifepristone) and further characterize examples that als

59 ed by the glucocorticoid receptor inhibitor, mifepristone, and a monoclonal antibody against the rece

60 y comparable to known GR antagonists such as mifepristone, and notably, this molecule lowers LDL (-74

61 nd medical therapies including ketoconazole, mifepristone, and pasireotide.

62 To explore the possibility of using mifepristone as a cancer metastasis chemopreventive, we

63 ort further exploration of GR antagonism via mifepristone as a therapeutic strategy for alcoholism.

64 ed the longer-term efficacy of 600 mg/day of mifepristone as an adjunctive treatment, for 1 week, in

65 ts point to a potential therapeutic role for mifepristone as an effective treatment for AD and furthe

66 udy did not detect a signal for efficacy for mifepristone at 600 mg/d for 1 week in male veterans wit

67 on rates in Ontario gradually increased with mifepristone availability in 2017 in Ontario.

68 till in place and bans physicians from using mifepristone based on any new developments in clinical r

69 After mifepristone became available as a normal prescription,

70 pite relatively good geographic coverage and mifepristone being available as a routine prescription,

71 The contraceptive drug mifepristone blocked PGCC formation and daughter cell fo

72 Systemic mifepristone blocks the reconsolidation of cue-condition

73 fter 24 h and the stimulation was blocked by mifepristone but not spironolactone.

74 appeals court stayed the full suspension of mifepristone, but permitted multiple restrictions on its

75 s showed that treatment with 1,000 mug/kg of mifepristone consistently switched on cTnT-Q92 expressio

76 cts of misoprostol, which were not shared by mifepristone, correlated with the activation of the G(s)

77 fepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profi

78 all ligands tested except for bicalutamide, mifepristone, DHT, and R1881 in a competitive binding as

79 Mifepristone did not exert its effect when administered

80 Postreactivation mifepristone did not impair short-term memory.

81 1.15-1.61) had poorer local availability of mifepristone-dispensing pharmacies.

82 ]) in BC lived within a 15-minute drive of a mifepristone-dispensing pharmacy.

83 females lived within a 15-minute drive of a mifepristone-dispensing pharmacy; however, despite relat

84 A combination of docetaxel and mifepristone (Doc + RU-486), an inhibitor of the glucoco

85 Finally, we show that the GR antagonist mifepristone does not block the expression of EtOH sensi

86 Despite the two-thirds reduction in mifepristone dose, success rates were high: Vietnam 93%,

87 nisolone and the pharmacologic GR antagonist mifepristone each acted directly on primary cultures of

88 erone and glucocorticoid receptor antagonist mifepristone, evident 2 weeks after the cessation of tre

89 medication) principally by a regimen of oral mifepristone followed 24 to 48 hours later by vaginal mi

90 implified medical abortion regimen of 200 mg mifepristone followed by the option of home administrati

91 Increasing access to mifepristone for EPL management may decrease health care

92 l timing of misoprostol administration after mifepristone for medical abortion is 2 days, but more fl

93 icate that mail-order pharmacy dispensing of mifepristone for medication abortion was effective, acce

94 Future studies of mifepristone for the treatment of PTSD may be of interes

95 en returned to the clinic up to 8 days after mifepristone for ultrasonographic evaluation.

96 A total of 15.6 (38.1%) in the mifepristone group and 12.1 (31.1%) in the placebo group

97 n was expected on the basis of trends before mifepristone had been available, whereas the percentage

98 nd cellular assays further demonstrated that mifepristone had the ability to prevent breast cancer ce

99 tive glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treat

100 Mifepristone has been available in Canada with a normal

101 The steroidal glucocorticoid antagonist mifepristone has been reported to improve the symptoms o

102 including through telehealth and mailing of mifepristone, has grown rapidly.

103 We also tested the use of mifepristone in 56 alcohol-dependent human subjects as p

104 ion together with an ultrasound, took 200 mg mifepristone in clinic and 800 mug misoprostol at home.

105 However, Mifepristone in combination with Tamoxifen did not incre

106 inistration of the glucocorticoid antagonist mifepristone in either the nucleus accumbens or ventral

107 their last menstrual period received 200 mg mifepristone in the clinic and then chose whether to tak

108 ed by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma

109 ential for progesterone-mediated reversal of mifepristone-induced abortion, this process has not been

110 ted for in vitro assessment on the basal and mifepristone-induced cell activation levels by FACS anal

111 Inhibition of proteasomal proteases in mifepristone-induced KO-WT, KO-GDP, or KO-GTP MEFs resul

112 erone administration following initiation of mifepristone-induced pregnancy termination (indicated by

113 ogesterone-mediated reversal of an initiated mifepristone-induced pregnancy termination in a rat mode

114 Our study explored the potential reversal of mifepristone-induced pregnancy termination using progest

115 Here, we exploited the mifepristone-induced SRC-3 LNCaP prostate cancer cell li

116 Hence, mifepristone induces a novel C-terminal cleavage of APP

117 Taken together, the mifepristone-inducible regulatory system provides a powe

118 by combination of liver-specific expression, mifepristone induction and Cre-loxP recombination to con

119 We also investigated the effects of local mifepristone infusions into the central amygdala (CeA) o

120 ly validated that escitalopram (Lexapro) and mifepristone inhibit hypertrophy of cultured cardiomyocy

121 Moreover, mifepristone inhibited the expression of focal adhesion

122 oid receptor (GR), whereas the GR antagonist mifepristone inhibits this response.

123 group was tested four hours after the Day 2 mifepristone injection to measure postreactivation short

124 In addition, we infused mifepristone into the basolateral amygdala (BLA) in etha

125 Mifepristone is an oral antiprogestational agent reporte

126 es and demonstrate that brief treatment with mifepristone is associated with a sustained improvement

127 In the United States, mifepristone is available for medical abortion (for use

128 The findings of this study suggest that mifepristone is underutilized for the medication managem

129 Postreactivation mifepristone may be a promising treatment for PTSD, but

130 Mifepristone may be a valuable pharmacotherapeutic strat

131 The effects of antiprogestin mifepristone (MF) on the growth, progesterone receptor e

132 Treatment with the antiprogestin mifepristone (MFP) inhibited growth of 59-2-HI tumors wi

133 Administration of the ligand mifepristone (MFP) up-regulated GHRH expression, as show

134 per-dependent adenoviral vector carrying the mifepristone (Mfp)-inducible gene-regulatory system to c

135 low basal cell activation in the absence of mifepristone (MFP).

136 Mifepristone-misoprostol abortion, consisting of oral pi

137 The mifepristone-misoprostol medication abortion regimen bec

138 ely tested two simplifications to the French mifepristone-misoprostol regimen in Vietnam and Tunisia.

139 This mifepristone-misoprostol regimen is effective in termina

140 oxin LPS or progesterone receptor antagonist mifepristone more often than current commonly used tocol

141 llet; the glucocorticoid receptor antagonist mifepristone neutralized TA inhibition of angiogenesis.

142 Mifepristone/olaparib combination therapy substantially

143 eline responding, we examined the effects of mifepristone on maintained responding and yohimbine-indu

144 Therefore, we investigated the effect of Mifepristone on the tumor necrosis factor alpha-related

145 eA plays an important role in the effects of mifepristone on yohimbine-induced reinstatement of ethan

146 (n = 10-16/group): Pregnant control (M-P-), mifepristone-only/pregnancy termination (M+P-) and mifep

147 nts were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progr

148 Proportion of pharmacies that could dispense mifepristone or provide a valid referral to a dispensing

149 -AR) (propranolol), glucocorticoid receptor (mifepristone), or CRHR1 (antalarmin).

150 GR antagonist mifepristone partially prevented CYP2R1 repression durin

151 ns (misoprostol alone or in combination with mifepristone), participants completed a baseline survey,

152 Of these patients, 3.0% received mifepristone plus misoprostol and 97.0% received misopro

153 59 (17%) of 348 women in the mifepristone plus misoprostol group did not pass the ges

154 62 (17%) of 355 women in the mifepristone plus misoprostol group required surgical in

155 Combination treatment with mifepristone plus misoprostol is more effective than mis

156 e was the medication used to manage EPL (ie, mifepristone plus misoprostol or misoprostol alone).

157 In multivariable analysis, use of mifepristone plus misoprostol was associated with decrea

158 Treatment with mifepristone plus misoprostol was more effective than mi

159 We investigated whether treatment with mifepristone plus misoprostol would result in a higher r

160 roxyprogesterone acetate, megestrol acetate, mifepristone, pregnanediol, 17alpha-hydroxypregnanolone,

161 en with missed miscarriage should be offered mifepristone pretreatment before misoprostol to increase

162 parent benefits, because coadministration of mifepristone prevented stress-induced disease ameliorati

163 ment of cells with the GR antagonist RU-486 (Mifepristone) prevented promoter activation by ePi.

164 Postreactivation, but not nonreactivation, mifepristone produced a decrement in the CR that did not

165 istone-only/pregnancy termination (M+P-) and mifepristone + progesterone (M+P+).

166 the glucocorticoid receptor (GR) antagonist mifepristone reduces alcohol intake in alcohol-dependent

167 We report that mifepristone reduces Klf15 expression across several in

168 of transgene expression using the GeneSwitch mifepristone-regulatable system within the context of an

169 Availability of mifepristone regulated as a normal (ie, prescribed by an

170 uced CTGF or 3T3 fibroblasts engineered with mifepristone-regulated CTGF were combined with LNCaP hum

171 Mifepristone-regulated gene expression was observed in s

172 ells engineered to express ps20-V5-His under mifepristone regulation showed a 129% increase in microv

173 h-3T3 cells engineered to express lacZ under mifepristone regulation.

174 ng Natural Language Processing (NLP) and 513 mifepristone-related genes were dug out and classified f

175 performed a systems pharmacology analysis of mifepristone-related molecules in the present study.

176 n and the glucocorticoid receptor antagonist mifepristone rescue Tau pathology in cytoplasmic hybrid

177 ng concentrations of cyproterone acetate and mifepristone resulted in more complete disruption of the

178 icient mice with the progesterone antagonist mifepristone (RU 486) prevented mammary tumorigenesis.

179 human progesterone receptor (hPR) inhibitor Mifepristone (RU-486) and other hPR ligands, a new class

180 plied the strategy to the photoactivation of mifepristone (RU-486), an antiprogestin drug that is als

181 gesterone was abrogated by the PR antagonist mifepristone (RU-486).

182 The glucocorticoid receptor (GR) antagonist mifepristone (RU-486; 10(-6) mol/L) blocked the inhibito

183 Chronic GR antagonism with mifepristone (RU38486) prevented the escalation of alcoh

184 We evaluated the ability of postreactivation mifepristone (RU38486, a glucocorticoid antagonist), alo

185 ntagonizing the glucocorticoid receptor with mifepristone (RU486) abrogated the reduction in Mtb cont

186 tment can also mediate NCoR recruitment, but mifepristone (RU486) at nanomolar concentrations is uniq

187 The potent human PR antagonist mifepristone (RU486) blocked PR-induced luciferase in bo

188 We previously showed that mifepristone (RU486) has anti-VEEV activity (EC(50) = 20

189 ts of the glucocorticoid receptor antagonist mifepristone (RU486) in the 3xTg-AD mouse model at an ag

190 Mifepristone (RU486), a synthetic steroid compound used

191 and cancer initiation/progression, we used a mifepristone (RU486)-inducible regulatory system to expr

192 n, antiglucocorticoid, and antiandrogen drug mifepristone (RU486).

193 e effects were reversed by the GR antagonist mifepristone (RU486).

194 mulated Luc activity, which was abolished by mifepristone (RU486).

195 ns in fish, and effects of the antiprogestin mifepristone (RU486, an abortive) are unknown.

196 armacological profile with the antiprogestin mifepristone (RU486; Roussel Uclaf SA).

197 ascularization are blocked by TA through the mifepristone-sensitive steroid receptor.

198 atment of these cells with the anti-GR agent mifepristone showed that they were more sensitive to thi

199 s and the glucocorticoid receptor antagonist mifepristone, the HPT axis-based treatments of thyroid h

200 In the presence of the antiprogestin mifepristone, this chimeric regulator binds to a target

201 the US Food and Drug Administration required mifepristone to be dispensed in person, limiting access

202 ifically in the liver by a brief exposure of mifepristone to induce permanent genomic recombination m

203 zebrafish liver only by a brief exposure of mifepristone to induce permanent genomic recombination m

204 design a combination treatment of TRAIL and Mifepristone to induce significant apoptosis in prostate

205 confirmed by the activation of caspase-8 in Mifepristone-treated cells.

206 ent phase and 1-week post-treatment phase in mifepristone-treated individuals.

207 In addition, mifepristone treatment also reduced the phosphorylation

208 Mifepristone treatment rescues the pathologically induce

209 Mifepristone treatment was associated with a time-limite

210 tory analysis, the difference in response to mifepristone vs placebo in the subgroup with no lifetime

211 , 5-year availability of normally prescribed mifepristone was associated with a rate difference of 1.

212 l of 195,183 abortions were performed before mifepristone was available and 84,032 after its availabi

213 o material changes between the period before mifepristone was available and the nonrestricted period

214 nalysis comparing trends in incidence before mifepristone was available with trends after its availab

215 ions of greater than 70 days on the date the mifepristone was dispensed that were not identified at s

216 When mifepristone was introduced in 2017 as a normal prescrip

217 PTSD and lifetime TBI, the response rate to mifepristone was lower than placebo at 12 weeks (7.4 [27

218 ned stable, as compared with the period when mifepristone was unavailable.

219 Mifepristone was well tolerated and improved liver-funct

220 Long-term administration of mifepristone was well tolerated but had no impact on pat

221 The effects of mifepristone were investigated in 3xTg-AD mice using a c

222 received misoprostol with pretreatment with mifepristone were less likely to have subsequent uterine

223 Neuroendocrine outcomes and plasma levels of mifepristone were measured.

224 s of human growth hormone in the presence of mifepristone whereas the transgene expression was undete

225 3 could be blocked by the steroid antagonist mifepristone, whereas hydrocortisone and other steroids

226 d molecules, epitiostanol, progesterone, and mifepristone, which decrease ferroportin levels by incre

227 g Administration (FDA)-approved protocol for mifepristone, which is used with misoprostol for medicat

228 posing as a patient with a prescription for mifepristone who requests to pick up the medication with

229 After the availability of mifepristone with a normal prescription, the abortion ra

230 Furthermore, we show that combining mifepristone with an approved SMN-directed gene therapy

231 mmunity pharmacies, 962 (66%) could dispense mifepristone within 3 days and 169 (12%) provided a vali

232 ients (30%) were able to complete 2 years of mifepristone without disease progression, adverse effect

233 A fifth group received mifepristone without the CS presentation (nonreactivatio